Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure - Activity relationship, molecular modeling, and biological studies

Journal of Medicinal Chemistry

Volumn 45, Issue 2, 2002, Pages 344-359

  Campiani, Giuseppe ^a   Butini, Stefania ^a   Gemma, Sandra ^a   Nacci, Vito ^a   Fattorusso, Caterina ^b   Catalanotti, Bruno ^c   Giorgi, Gianluca ^a   Cagnotto, Alfredo ^d   Goegan, Mara ^d   Mennini, Tiziana ^d   Minetti, Patrizia ^e   Di Cesare, M Assunta ^e   Mastroianni, Domenico ^e   Scafetta, Nazzareno ^e   Galletti, Bruno ^e   Stasi, M Antonietta ^e   Castorina, Massimo ^e   Pacifici, Licia ^e   Ghirardi, Orlando ^e   Tinti, Ornella ^e   Carminati, Paolo ^e   more..

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF SALERNO   (Italy)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^e Sigma Tau SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

7 CHLORO 9 (4 METHYLPIPERAZIN 1 YL) 9,10 DIHYDROPYRROLO[2,1 B][1,3]BENZOTHIAZEPINE; ALPHA 1 ADRENERGIC RECEPTOR; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; HISTAMINE H1 RECEPTOR; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; PYRROLO[1,3]BENZOTHIAZEPINE DERIVATIVE; SEROTONIN ANTAGONIST; ST 1460; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING KINETICS; BIOLOGICAL MODEL; CATALEPSY; CHEMICAL STRUCTURE; DOPAMINE RELEASE; DRUG ABSORPTION; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ENANTIOMER; MOLECULAR MODEL; NONHUMAN; PROLACTIN BLOOD LEVEL; PSYCHOSIS; RAT; RECEPTOR AFFINITY; STEREOCHEMISTRY; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; X RAY DIFFRACTION;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; BRAIN; CATALEPSY; CRYSTALLOGRAPHY, X-RAY; DOPAMINE; DOPAMINE ANTAGONISTS; HOMOVANILLIC ACID; MALE; MICE; MICRODIALYSIS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; PROLACTIN; PYRROLES; RADIOLIGAND ASSAY; RATS; RATS, INBRED F344; RATS, WISTAR; RECEPTORS, DOPAMINE D2; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZEPINES;

EID: 0037122780     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm010982y     Document Type: Article

References (50)

1. The current status of the dopamine hypothesis of schizophrenia
2. Clinical studies on the mechanism of action of clozapine: The dopamine-serotonin hypothesis of schizophrenia
3. 2 adrenoceptor blockade
4. 2-adrenoceptor antagonists
5. 2 receptor antagonists in schizophrenia: Preclinical and clinical considerations
6. Clozapine-induced agranulocytosis. Incidence and risk factors in United States
7. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril national registry
8. Atypical antipsychotic agents: A critical review
9. Receptor pharmacology of neuroleptics: Relation to clinical effects
10. Olanzapine: A basic science update
11. Olanzapine - A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychosis
12. Safety of olanzapine
13. The safety of olanzapine compared with other antipsychotic drugs: Results of an observational prospective study in patients with schizophrenia (EFESO study)
14. The pharmacology of olanzapine and other new antipsychotic agents
15. Olanzapine-induced agranulocytosis
16. A comparison of covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo
17. Comparison of the oxidation of clozapine and olanzapine to reactive metabolites and the toxicity of these metabolites to human leucocytes
18. New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]-benzothiazepine structure
19. Conformational analysis and structural comparisons of (1R,3S)-(+)- and (1S,3R)-(-)-tefludazine, (S)-(+)- and (R)-(-)-octoclothepin, and (+)-dexclamol in relation to dopamine receptor antagonism and amine-uptake inhibition
20. 2 receptor antagonists
21. Sintesi e proprietá farmacologiche di n-isopropilfeniletanolammine orto- meta- o para sostituite
22. Anomalous reaction of pentafluorophenacyl bromide with examethylenetetramine, structure of the product
23. A facile and convenient synthesis of the unknown 1-aroylmethyl-1H-pyrroles
24. Polycondensed heterocycles. VIII. Synthesis of 11-aryl-5H, 11H-pyrrolo[2,1-c][1,4]benzothiazepines by Pummerer rearrangement - Cyclization reaction
25. Interrupted Pummerer rearrangement: Capture of tricoordinate sulfur species generated under Pummerer rearrangement conditions
26. Polycondensed heterocycles. VII. A convenient synthesis of pyrrolo[1,2-α]quinoxaline derivatives by intramolecular aromatic nucleophilic displacement
27. 2 pki values
28. A decade of serotonin research: Role of serotonin in treatment of psychosis. Serotoninergic basis of antipsychotic drug effects in schizophrenia
29. The role of serotonin in pathophisiology and treatment of schizophrenia
30. 2 dopamine receptor blockade
31. 2C receptor subtypes and significance of the haloperidol dose used
32. Endogenous serotonin enhances the release of dopamine in the striatum only when nigro-striatal dopaminergic transmission is activated
33. Role of serotonin 2B\2C receptor subtypes in the control of accumbal striatal dopamine release elicited in vivo by dorsal raphe nucleus electrical stimulation
34. Selective blockade of serotonin-2C\2B receptors enhances mesolimbic and mesostriatal dopaminergic function: A combined in vivo electrophysiological and microdialysis study
35. Role of striatal serotonin 2A and serotonin 2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum
36. Differential effects of caloperidol, clozapine and fluperlapine on tuberoinfundibular dopamine neurons and prolactin secretion in the rat
37. Conformational properties of semi-rigid antipsychotic drugs: The pharmacophore for dopamine D-2 antagonist activity
38. Simultaneous analysis of families of sigmoidal curves: Application to bioassay, radioligand assay and physiological dose - Response curves
39. 50) of an enzymatic reaction
40. Climbing behaviour induced by apomorphine in mice: A potential model for detection of neuroleptic activity
41. 1192U90 in animal tests that predict antipsychotic efficacy, anxiolysis, and extrapyramidal side effects
42. The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent
43. Rapid tolerance to neuroleptic-induced stimulation of dopamine release in freely moving rats
44. Effects of age and dopamine agonist and antagonist on striatal dopamine release in the rat, an in vivo microdyalisis study
45. Structure and energetics of ligand binding to proteins
46. Unconstrained optimization
47. MOPAC: A semiempirical molecular orbital program